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ABSTRACT
Cumulative exposure to estrogen (E) and progesterone (P) over the menstrual 
cycle significantly influences the risk of developing breast cancer. Despite the dogma 
that PR in the breast merely serves as a marker of an active estrogen receptor (ER), 
and as an inhibitor of the proliferative actions of E, it is now clear that in the breast P 
increases proliferation independently of E action. We show here that the progesterone 
receptor (PR) and ER are expressed in different epithelial populations, and target 
non-overlapping pathways in the normal human breast. In breast cancer, PR becomes 
highly correlated with ER, and this convergence is associated with signaling pathways 
predictive of disease metastasis. These data challenge the established paradigm that 
ER and PR function co-operatively in normal breast, and have significant implications 
not only for our understanding of normal breast biology, but also for diagnosis, 
prognosis and/or treatment options in breast cancer patients.
INTRODUCTION
Cumulative exposure to estrogen (E) and 
progesterone (P) throughout a woman’s reproductive life 
significantly influences the overall risk of developing 
breast cancer [1], and the evidence that ovarian hormones 
are major drivers of breast cancer risk is irrefutable [2, 
3]. Ovariectomy decreases breast cancer risk, while 
early menarche, late menopause, and late first full-term 
pregnancy are associated with an increase in breast cancer 
risk [4]. Similarly, increased breast cancer risk associated 
with synthetic progestins in exogenous formulations, such 
as oral contraceptives and hormone replacement therapy 
(HRT), further highlights the role of ovarian hormones in 
breast cancer [5, 6], yet the respective roles of E and P in 
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the breast remain undefined.
Development of the normal breast is driven by 
the endocrine environment, with breast proliferation 
occurring in puberty [7], during the menstrual cycle [8, 
9], and in pregnancy. In animals, E and P have distinct 
activities in mammary development, with E regulating 
ductal elongation [10] and P regulating side-branching 
and lobular development [11]. Expression of the nuclear 
receptors, estrogen receptor (ER) and progesterone 
receptor (PR), through which E and P exert their effects, 
supports the view that these hormones have distinct roles 
in normal human breast [8, 9]. ER is cyclical over the 
menstrual cycle, expressed in the follicular phase of the 
menstrual cycle but virtually absent in the luteal phase 
and pregnancy [12], when PR is expressed [13]. The 
proportion of ER+ cells significantly increases with age 
to a plateau at menopause [14], whereas this same age-
related change is not seen for PR. There is also increasing 
evidence that full-term pregnancy induces long-term 
gene expression changes in the breast [15], with parous 
individuals displaying lower expression of ER and PR 
than nulliparous subjects [16-18]. 
Despite the complexity of E and P action in the 
breast, and the heterogeneity of ER and PR in the gland, it 
has long been believed that ER and PR are co-expressed in 
the same cells, and that PR merely serves as a marker of an 
active ER, and as an inhibitor of the proliferative actions 
of E. This view is challenged by evidence that P increases 
normal breast proliferation independently of E action, 
and that PR is expressed independently of E stimulation. 
Moreover, normal breast progenitor cells do not show the 
same pattern of ER and PR expression, supporting distinct 
roles for E and P in breast epithelial development [19, 20]. 
Although there is a paucity of data on the roles of 
E and P in normal breast, it has long been known that 
over 60% of breast cancers contain both ER and PR. 
The presence of ER and PR is the single most important 
predictive marker for positive endocrine responsiveness 
[21] yet molecular profiling has identified subgroups 
within ER+PR+ tumors with widely different prognoses, 
for example the Luminal B subgroup of ER+PR+ 
tumors with high proliferation and poor prognosis [22]. 
Consequently, expression of ER and PR are important 
but not definitive predictors of prognosis, and indicators 
of prognosis that incorporate both the expression and 
functional significance of these steroid receptors are 
urgently needed. In this study, we have examined a range 
of human cohorts and used in vivo, in vitro and in silico 
approaches to identify distinct pathways associated with 
ER and PR in normal breast, and the convergence of 
their action in breast cancer, to derive ER-PR focussed 
prognostic tools to identify different prognosis groups 
within breast cancers with otherwise good prognosis. 
RESULTS
Expression of ER and PR is non-overlapping in 
normal human breast and mouse mammary gland
Individual ER and PR expression in the normal 
breast is known to be markedly heterogeneous, but there 
Figure 1: ER and PR expression in normal human breast. A Representative IF images of normal breast tissue sections from 
4 individual donors stained for ER (red) or PR (green). Scale bars represent 50 μm. B Boxplots (displaying the minimum, first quartile, 
median, third quartile, maximum and outliers) of the proportions of (i) ER+ or PR+ cells (ii) ER+/PR+ co-expressing cells, (iii) ER+ only 
cells, and (iv) PR+ only cells in a series of normal human breast tissue samples (n = 22).
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are few data that have specifically determined whether 
ER and PR are expressed in the same cells. In a cohort 
of normal human breast samples (22 independent samples 
from 20 patients), we revealed extensive heterogeneity 
in the combined expression of these steroid hormone 
receptors (HR) in HR+ cells, both within the same breast, 
and between individual samples (Figure 1A and Supp Fig 
1A). Expression of a single HR (ER or PR) was more 
common than co-expression of ER and PR (Figure 1B). 
In this sample cohort, a median of 5.9% (range 0-38%) of 
epithelial cells counted overall co-expressed ER and PR, 
while 10.1% (range 2.4-32.2%) expressed only one HR. 
Although the single HR+ cells more frequently expressed 
ER (median 6.6%; range 0-32%) than PR (median 0.4%; 
range 0-14%), there were several individual samples 
which contained more PR+ only cells than ER+ only 
cells (Supp Fig 1A), evidence that the lower levels of 
PR positivity were not due to an underestimate of PR 
expression. Furthermore, the lack of overlap in ER and 
PR co-expression was clearly evident when sections were 
stained for only one HR (Supp Fig 1B). There was no 
correlation between the proportion of HR positivity and 
age (Supp Fig 1C). 
Similar to human breast tissue, ER and PR showed 
distinct expression patterns in the mouse mammary 
epithelium at various stages throughout the estrous 
cycle (Figure 2). Circulating levels of E and P rise and 
fall during the murine estrous cycle, which results in 
fluctuating activation of ER and PR. This in turn is 
followed by changes in levels of gene transcription, which 
affect not only the cells expressing ER and/or PR, but also 
neighbouring cells via paracrine signalling [2, 23, 24]. 
The levels of E peak at late proestrous (pre-ovulation) 
and fall throughout estrous, whereas P levels peak during 
diestrous [24]. In post-pubertal elongating mammary 
glands taken from mice at 5 wks age, ER expression was 
widely expressed by the cells of the proliferating terminal 
end buds and the luminal epithelium (Figure 2Ai), in 
contrast PR expression is less widely distributed. Thus 
in the elongating mammary gland there are both steroid 
receptor negative and positive cells, and a population of 
cells that express ER, but have low or no expression of 
PR. These observations reinforce the importance of E 
(but not P) for mammary ductal elongation, illustrated 
by mammary gland reconstitution experiments using ER-
/- and PR-/- mammary epithelium showing that ER, but not 
PR, is necessary for this stage of mammary development 
[25, 26]. 
Different patterns of steroid receptor expression 
were observed in the adult mammary gland (Figure 
2ii - iv). In contrast to the elongating mammary gland, 
ER and PR expression was restricted to a subset of 
luminal epithelial cells with fewer cells expressing 
ER. At diestrous, when P levels are high, elevated PR 
expression was seen (Figure 2Biii). When E levels surge 
pre-ovulation, so did the expression of ER, with PR levels 
remaining high (Figure 2iv). In adjacent sections taken 
from adult mammary glands, we observed that there were 
both steroid receptor negative and positive cells, plus a 
proportion of luminal epithelial cells that expressed PR 
with low or no expression of ER. These observations are 
consistent with previous investigations [27] and fit with 
Figure 2: ER and PR expression in mouse mammary gland. Representative IPX images of adjacent sections of mouse mammary 
gland showing (A) ER and (B) PR expression at (i) 5 week virgin, (ii) estrous, (iii) diestrous, and (iv) proestrous. Scale bars represent 50 
μm.
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the indispensable role of P-stimulated mammary epithelial 
cell proliferation during branching morphogenesis [25, 
28]. Hence the distinct actions of E and P, acting on their 
cognate receptors in the mammary epithelium, support the 
notion that the mouse mammary gland contains distinct 
cellular populations that respond to systemic hormonal 
cues in a context-dependent manner at different stages 
of development. Therefore, in contrast to the general 
acceptance that HRs are always co-expressed, we have 
demonstrated here that in both the human breast and 
mouse mammary gland the expression of ER and PR is 
highly heterogeneous and largely non-overlapping.
ER and PR transcripts are enriched in 
functionally distinct cell subsets in the normal 
human breast
To examine the presence of ER and PR in luminal 
and basal epithelial cell subpopulations, we isolated these 
subsets from normal breast samples. ER transcripts were 
highly enriched in each luminal cell fraction, in contrast 
with PR transcripts, which were enriched in the basal and 
bipotent progenitor fractions (Figure 3A and Supp Fig 
2) [20]. ER protein expression was only detected in the 
luminal subpopulation (Figure 3Bi), while PR protein 
was markedly heterogeneous between individuals (Figure 
3Aii), and detected in both subpopulations (Figure 3Bii), 
recapitulating the transcript data. As we [29] and others 
[30-33] have shown, CD10+ cells display enhanced 
colony forming ability with a higher proportion of colonies 
displaying a bipotent progenitor phenotype. This suggests 
that segregation of ER and PR transcripts in fractionated 
cell subsets based on different lineage markers may reflect 
functional differences in the normal breast. Thus, this 
demonstration of enrichment of ER and PR (transcripts 
and protein) in distinct cell compartments in an in vitro 
3D culture model of normal breast tissue supports the IF 
staining of breast tissue sections in vivo depicted in Figure 
1. 
Increasing co-expression of ER and PR in pre-
invasive breast lesions and in breast tumors 
are associated with lineage composition and 
proliferation
We measured ER and PR in pre-invasive lesions 
(columnar cell lesions (CCL; n=22), DCIS samples; n=22) 
Figure 3: ER and PR expression in luminal and basal cell subsets. A Relative mRNA levels of ER (i) and PR (ii) were 
normalised to TBP in basal CD10+ and luminal MUC1+ subpopulations. Graphs represent the mean + SE in independent experiments 
using tissue from 3 different patients. B Representative images showing IPX staining for (i) ER and (ii) PR in sorted CD10+ and MUC1+ 
fractions. Scale bar represents 25 μm.
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and invasive breast tumor samples (n=7). Compared with 
normal breast tissue, the pre-invasive lesions showed 
higher numbers and a wider range in the proportion of 
cells co-expressing ER and PR, ranging from 0% to ∼85% 
(Figure 4A and Supp Fig 3A). The tumor samples also 
contained significantly higher numbers of ER+/PR+ co-
expressing cells, compared with both normal breast tissue 
and pre-invasive samples. There was no consistent change 
in the proportion of single ER+ or PR+ cells across the 
sample cohort, although there were much higher numbers 
of single ER+ cells overall, compared with single PR+ 
cells (Supp Fig 3B and 3C). These data show that ER and 
PR expression become more highly correlated in breast 
tumor samples, than in normal breast.
Cancers show progressively fewer myoepithelial 
cells relative to luminal cells as they progress through 
premalignant to malignant stages [34]. We compared 
luminal to myoepithelial cell ratio and proportion of ER+/
PR+ cells in this cohort and found an increased proportion 
of ER+/PR+ cells in cancers where myoepithelial cells 
were lower (correlation coefficient = 0.334, p=0.007, 
Spearmans Rank correlation; Figure 4B). There was 
a significant correlation between lineage composition 
and proportion of cells expressing only ER (correlation 
coefficient = 0.509, p<0.0001, Spearmans Rank 
correlation, not shown), but no correlation with cells 
expressing only PR (correlation coefficient = -0.169, 
p=0.183, Spearmans Rank correlation, not shown). The 
expression of ER was also associated with proliferation 
(as measured by the proportion of Ki67+ cells [34]), 
as reflected by the significant correlation between 
proliferation and the proportion of cells expressing only 
ER (correlation coefficient = 0.269, p=0.03, Spearmans 
Rank correlation). These data raise the possibility of a role 
for E in pre-invasive lesions, and suggest that E may drive 
increased proliferation in luminal cells within these lesion 
types.
ER and PR are functionally non-overlapping in 
normal human breast
The non-overlapping expression of ER and PR 
in normal breast was validated in independent cohorts 
(normal breast n=50; breast cancer n=66), where we had 
previously measured the transcript expression of ER, PR 
and the other members of the nuclear receptor (NR; n=48) 
gene family, and all known NR co-regulators (CoRs; 
n=238) [35]. This showed that ER and PR transcript 
levels were not correlated in normal breast (left panel, 
Figure 5A), confirming the immunohistochemical data. 
In further support, ontology analysis of genes regulated 
by P in the normal breast in 3D culture [19], and by E 
in normal breast xenografts in nude mice [36], revealed 
that E and P regulated non-overlapping functional 
pathways (Table 1). Whereas E regulated transcripts were 
involved in extracellular signalling, P regulated processes 
were associated with cell growth (RNA processing, cell 
cycle), consistent with its demonstrated stimulation 
of proliferation in the breast. In contrast to these non-
overlapping pathways, there were only 3 broad categories 
which contained genes regulated by both E and P, and 
these had relatively low enrichment scores (Table 1); the 
individual functions of E and P in the normal human breast 
are thus distinct. To further explore the functional overlap 
of ER and PR in normal breast, we identified all NR and/
or CoRs that correlated with ER or PR in the normal breast 
cohort (n=50). There were 35 genes in total that correlated 
with ER and 32 with PR, but none correlating with both 
ER and PR (Supp Fig 4A), supporting the findings in 
Table 1. 
Figure 4: ER and PR expression in a cohort of normal, pre-invasive and breast tumor samples. A Boxplots of the 
proportions of ER+/PR+ co-expressing cells across a spectrum of normal (norm; n=22), CCL (n=22), DCIS (n=22) and invasive breast 
cancer (CA; n=7) samples. ** = p<0.001, * = p<0.01. B Scatter plot of distribution of luminal to myoepithelial ratio and percentage of ER+/
PR+ co-expressing cells. 
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ER and PR become correlated in breast cancer 
and converge on common pathways involved 
in cytokine signaling, cell cycle control, and 
pluripotency
In contrast with normal breast, ER and PR 
transcripts became highly correlated in breast cancers 
(right panel, Figure 5A). To identify whether this was 
associated with functional overlap, we identified 120 NR 
and CoR genes that correlated with either ER or PR in 
breast cancers (n=66). Whereas in normal breast ER and 
PR were correlated with non-overlapping sets of NRs and 
CoRs, we identified genes (n=22) that were correlated 
with both receptors only in breast cancer. Moreover, 
Ingenuity network analysis of NR and CoR genes that 
were highly correlated with PR in breast cancers, but not 
normal breast, revealed an ER (ESR1)-centred network 
of genes (Figure 5B). Upstream regulator analysis 
revealed that E was the most common shared upstream 
regulator of PR correlated genes, showing that PR-
correlated genes become E-regulated in cancer. NUR77, 
Table 1: Ontology analysis of E-regulated functional 
pathways compared with P-regulated, and combined 
E/P-regulated pathways in normal human breast
E Regulation
Summary function
Enrichment 
score
Chemokine signalling 3.77
Extracellular signalling
Hormone response
2.89
2.85
Extracellular metabolism 2.34
P regulation
Summary function
Enrichment 
score
RNA processing 9.77
Macromolecule assembly 3.29
Cell cycle 3.27
Mitochondrial organisation
Cell cycle regulation
2.97
2.40
Serine peptidase inhibition 2.21
ECM binding 2.03
Combined E and P regulation
Summary Function
Enrichment 
score
Wound response
Cell adhesion
Hormone response
2.68
2.40
2.12
Figure 5: ER and PR transcripts and correlated networks in an independent cohort of normal and breast cancer 
samples. A Scatter plot of ΔCt values obtained for ER (ESR1) and PR (PGR) in normal breast vs cancer samples profiled on TLDAs. B 
Merged ER and PR correlated networks in (i) normal, and (ii) breast cancers. Genes which also correlate with ER are shaded in blue. Also 
indicated are genes which are activated (red) or inhibited (green) by E.
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NRIP1 and RNF4 signalling is activated by E (shown 
in red), whereas SMAD3, STAT3 and PNRC2 regulated 
functions are inhibited by E (shown in green). NUR77 is 
frequently elevated in cancers [37] and NRIP1 promotes 
mitogenic signalling in the developing mammary 
gland [38], while SMAD3 and STAT3 are known to be 
fundamental mediators of growth factor and cytokine 
signalling. Furthermore, from our dataset of PR genomic 
interactions in breast cancer cells [39], we have identified 
PR binding sites close to all six of these PR correlated 
genes (Supp Table 1), suggesting that they may be directly 
PR regulated. 
These data, discovered in robustly validated 
cohorts of human tissues, demonstrate that PR signalling 
converges with that of ER in breast cancers, in an 
interplay that does not exist in normal tissue. Moreover, 
to determine the functional significance of this converged 
E and P signalling, Ingenuity overlapping pathways 
analysis of this network and its direct connections revealed 
significant over-representation of pathways associated with 
cell cycle control, cytokine signalling and maintenance of 
pluripotent state (Supp Fig 4B). This demonstrates that 
genes correlated with PR and ER in breast cancer are 
involved in pathways crucial to cancer cell development 
and function. Therefore, we have shown in an additional 
sample cohort using alternative methodologies that ER 
and PR transcripts do not correlate in normal breast tissue, 
and become more highly correlated in breast tumors. This 
is supported by the demonstration that ER and PR each 
correlate with non-overlapping transcriptional networks 
in normal breast, but that ER and PR networks overlap in 
breast cancer. 
Figure 6: Expression of 18 genes predicts poorer prognosis Kaplan Meier plot of probability of survival where patient 
samples from the (A) METABRIC breast cancer microarrays, or (B) from three different datasets (GSE25055, GSE25065, 
GSE7390), were stratified into low or high risk groups based on low (blue) or high (orange) expression of the 18 genes found 
to be correlated with both ER (ESR1) and PR (PGR) expression in cancers. C Kaplan Meier plots of patient samples from Luminal 
A tumors (left panel) or Luminal B tumors (right panel) in the METABRIC dataset were stratified into low or high risk groups.
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Expression of genes highly correlated with both 
ER and PR in breast cancers are associated with 
distinct clinical outcomes
Using the METABRIC breast cancer microarray 
dataset of 1853 samples [40], we identified 18 genes that 
were highly correlated with both ER and PR (Spearman 
Rank Correlation >= 0.5) in both the discovery and 
validation cohorts (Supp Table 2). Although the function 
of a large number of these genes is not known, there 
were a number of metabolic markers, for example, NAT1 
[41] and ABAT [42]. Interestingly, 10 of the 18 genes 
contained both ER and PR binding regions within 50 
kb of their transcription start sites (indicated in Supp 
Table 2), and most of these genes contained ER and PR 
overlapping binding sites (indicated in Supp Table 3). To 
determine the clinical significance of these 18 genes, we 
tested the association between this gene signature and 
patient survival in the METABRIC dataset [40]. Sample 
risk scores calculated based on the combined weighted 
expression of the 18 genes in the signature showed 
significant correlation with distant metastasis-free survival, 
with higher risk scores correlating with poorer prognosis 
(Figure 6A; Cox p value = 1.23x10-11). Importantly, this 
persisted even when accounting for node status and ER/
PR expression, indicating that this signature can identify 
patients with risk of earlier metastasis, independent of ER 
and PR status. The association between expression of the 
18 gene signature and patient prognosis was also validated 
in three independent breast cancer microarray datasets 
(GSE25055, GSE25065 and GSE7390; Figure 6B). 
Finally, we looked at the association between 
expression of the 18 gene signature and distant metastasis-
free survival within particular tumor subtypes. The levels 
of expression of this 18 gene signature were able to 
identify differences in prognosis both within the Luminal 
A subtype, and to a higher degree within the Luminal B 
intrinsic subtypes (Figure 6C). Furthermore, lower risk 
scores calculated based on the expression of the 18 gene 
signature identified patients with a better prognosis only 
in a unique subset of these tumors expressing high levels 
of PR but low levels of ER (Supp Fig 5). Interestingly, 
the gene signature also identified patients with a better 
prognosis in ER- tumors (data not shown), although this 
was less significant. Therefore, by measuring the ER-PR 
correlated 18 gene signature in a number of highly curated 
datasets, we have identified a prognostic signature which 
identifies patients with ER+PR+ breast cancer who are at 
risk of earlier metastasis, particularly in Luminal B cases, 
and can thus predict poorer outcome independent of ER 
or PR status. 
DISCUSSION
This study demonstrates that in the normal human 
breast, the expression of ER and PR do not correlate and 
that their functions are largely non-overlapping. This 
expression pattern of ER and PR is also seen in a cohort 
of pre-invasive lesions. In contrast, we show that ER 
and PR become highly correlated in breast cancer, and 
that their actions converge. Finally, we have identified a 
novel potential prognostic gene signature which identifies 
patients with ER+PR+ breast cancer at risk of earlier 
metastasis. Importantly, these data were obtained using a 
combination of both human and mouse samples, transcript 
and protein data, multiple sample cohorts, and in vitro, in 
vivo and in silico methods. 
The expression of ER and PR is highly 
heterogeneous in the normal breast, both inter- and intra-
individually, and there is large variation in intensity of 
expression of each HR, which results in a rainbow-like 
appearance in stained sections. Aside from natural inter-
individual variation, these variable proportions of cells 
expressing only one HR, or both, is likely to be due to 
differences in menstrual cycle phase, exogenous hormone 
use and/or parity, information which was not available 
to us. The sequence of antibodies applied is of critical 
importance to accurately reflect the heterogeneous 
expression (Supp Fig 6), but heterogeneity is still evident 
when mirror sections are stained with only one HR (Supp 
Fig 1B). Identification of ER and PR transcripts in different 
cell compartments based on various progenitor or mature 
cell markers suggests that both HRs can be expressed 
individually, and at multiple stages of the epithelial cell 
hierarchy. Indeed, we have previously shown that ER, and 
to a greater extent PR, can be expressed in basal cells, 
functionally and phenotypically consistent with being 
progenitor cells [20]. Intriguingly, we observed these 
HR+ progenitor cells expressed only ER or PR, but not 
both, and so it is tempting to speculate that, in the normal 
breast, a subset of the cells which express only one HR, 
are progenitor cells.
Heterogeneous HR expression is also evident in 
pre-invasive breast lesions. The CCLs and DCIS lesions 
are associated with significantly higher risks for tumor 
formation, and the relative risk increases progressively 
according to the histological subtype of the lesion. While 
variable risk ranges have been reported, the relative risk 
factors are accepted to be ∼1.5 for CCL and ∼10 for DCIS 
[43, 44]. It is important to note the wide distribution 
of ER+/PR+ co-expressing cells in the pre-invasive 
lesions, and it would be interesting to determine whether 
those with higher proportions of co-expressing cells are 
indicative of convergence of ER and PR. Such lesions may 
be more pre-disposed to development of steroid receptor-
positive tumor formation, in which case HR co-expression 
may serve as an additional marker of prognostic 
significance. Moreover, it is tempting to speculate that 
lesions expressing more ER, or PR, or co-expressing both, 
may give rise to tumors of different phenotypes. 
The correlation between the proportion of luminal 
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cells, and the proportion of cells expressing either ER 
only, or both ER and PR, highlights a potential role for ER 
in lineage re-modeling in carcinogenesis. As an increase 
in proportion of luminal cells correlates with increasing 
severity of the lesion [34], this supports the notion that 
ER expression, and ER/PR co-expression, are also more 
highly correlated with increasing severity. The lack of 
correlation between increased luminal cell numbers with 
increased PR+ only cells however, raises the possibility 
that ER-/PR+ tumors may be more likely to resemble basal 
tumors. Indeed, a recent study reported that the majority of 
ER-/PR+ tumors examined were in fact basal-like tumors 
[45]. This would also be consistent with the possibility 
that these tumors may arise from PR+ bipotent progenitor 
cells. 
In ER+PR+ breast tumors, the proportion of cells 
expressing these HRs is commonly higher than in the 
normal breast [46], thus the increased proportion of 
ER+/PR+ co-expressing cells might reflect a higher 
probability of each HR being expressed in the same 
cell. Alternatively, more luminal lesions may arise from 
ER+/PR+ co-expressing cells. In the present study we 
did not distinguish individual steroid receptor isoforms. 
Previous studies have shown, however, that in the 
earlier stages of carcinogenesis increased levels of ERα 
are expressed, with a clear dissociation between ER 
expression and proliferation [1]. Furthermore, the ERβ 
isoform is preferentially lost in some cancers, whereas its 
introduction slows the growth of breast cancer cells [47], 
supporting the notion that dysregulation of HR expression 
either contribute to, or accompany breast tumorigenesis. 
The lack of overlap in the normal breast between 
the regulatory pathways correlated with either ER or PR 
is striking, underlining the independent action of each 
hormone in the normal breast. In contrast, this study 
shows that E and P have converging roles in breast cancer, 
specifically on pathways associated with cell cycle control, 
cytokine signaling and stem cell regulation, all commonly 
up-regulated during tumorigenesis. Moreover, E stimulates 
human breast cancer stem cells (CSCs) [48], as do P and 
progestins [29, 49, 50]; there are also data that E reduces 
stem cell frequency in breast cancer [51]. As breast tumors 
are postulated to arise from carcinogenic transformation 
of stem/progenitor cells [52], it will be critical to identify 
whether E and P signaling converges in distinct cell types 
within the epithelial hierarchy during tumorigenesis, 
potentially giving rise to different breast cancer subtypes. 
Finally, identification of pathways common to 
both ER and PR in breast cancer has yielded an 18 gene 
signature associated with higher risk of early metastasis. 
High expression of a number of these genes has also been 
identified in previous studies to be linked to a poorer 
prognosis, for example, SIAH2 [53], and NAT1 and 
SCUBE2 [54]. Interestingly, SCUBE2 is the only gene 
in common between the genomic assays, Oncotype DX 
and MammaPrint. The 18 gene signature identified in this 
study was rich in metabolic markers, and it has long been 
known that tumor cells display higher rates of glycolysis, 
believed to promote unconstrained proliferation [55]. 
Thus this gene signature may identify tumors which have 
a significant growth advantage and thus likely to have a 
poorer outcome. It must also be noted that the functions of 
10 of the 18 genes remain unknown, and identification of 
function of these genes has the potential to discover novel 
pathways with a role in driving increased breast cancer 
risk.
There are common misconceptions regarding the 
role of E and P in the breast, which largely derive from 
what we understand of their functions in the uterus, where 
proliferation occurs prior to ovulation and post-ovulatory 
secretion of P inhibits proliferation. Moreover, current 
thinking supports the idea that PR expression is mediated 
by ER activation, again reflecting uterine biology. The 
findings of this study clearly demonstrate that the current 
understanding of E and P action in the normal human 
breast, and expression of their receptors, has important 
consequences, and urgently needs to be re-evaluated. 
For example, such a high degree of heterogeneity in 
HR expression within the population would mean that 
administration of exogenous hormone formulations such 
as HRT or the oral contraceptive pill would have vastly 
different effects in different people. Moreover, E and P 
within these hormone formulations would largely not 
be targeting the same cells. The findings also support 
the hypothesis that PR acquires the capacity to interact 
with the ER pathway in breast cancer, and that their 
combined action impacts on breast cancer development 
and progression, particularly where endogenous hormone 
cyclicity is disturbed, such as in peri-menopause and 
during HRT exposure. As HRT is one of the most 
frequently administered pharmaceuticals world-wide, 
delineating the mechanisms of an altered interaction 
between PR and ER in cancer is crucial to unravelling the 
mechanisms that underlie the role of HRT progestins in 
breast cancer, and would lead to potential strategies for 
continued development and administration of hormone 
formulations. Moreover, delineating the mechanisms 
of an altered interaction between PR and ER in cancer 
may identify potential indicators of breast cancer risk, 
prognosis and/or treatment options.
As ER and PR status are routinely assessed in all 
newly diagnosed invasive breast tumours and in breast 
cancer recurrences, as well as their expression being 
the most important predictive marker for prognosis 
and response to endocrine therapy, these findings have 
critical implications for decisions made regarding 
diagnosis, prognosis and/or treatment options in 
breast cancer patients. Moreover, as the action of these 
hormones underpins both normal development and breast 
tumorigenesis, the data presented here suggest that the 
current concepts of how these hormones interact requires 
re-evaluation.
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MATERIALS AND METHODS
Tissue samples
Normal (n = 18) and ductal carcinoma in situ 
(DCIS; n = 20) breast tissue samples, and 2 tissue 
microarrays (TMAs; consisting of normal breast tissue, 
columnar cell lesions, ductal carcinoma in situ samples 
and tumor samples) which expressed ER and/or PR (>5% 
positive of epithelial cells counted) were obtained from the 
Australian Breast Cancer Tissue Bank (http://www.abctb.
org.au). Data obtained from breast tissue samples from 
the cohort described in Muscat et al., 2013 [35] were also 
used. Normal human breast tissue samples obtained from 
reduction mammoplasty specimens were obtained with 
informed consent from donors, and the use of all samples 
was approved by Human Research Ethics Committees of 
the Sydney West Area Health Service, the University of 
Sydney, and the Sydney Adventist Hospital, New South 
Wales, Australia. All mouse work was approved and 
conducted under the guidelines of the Garvan/St. Vincent’s 
Animal Ethics Committee. Nulliparous wild type FVB/n 
mice were collected at 5 wks estrous (n=3), 12 wks estrous 
(n=3), 12 wks diestrous (n=2) and 12 wks pro-estrous 
(n=1). Estrous staging was performed using cytological 
examination of DiffQuik stained vaginal smears according 
to manufacturer’s instructions (Fisher Scientific).
Fluorescence-activated cell sorter (FACS) analysis
Normal human mammary epithelial cells (MECs) 
were isolated from reduction mammoplasty specimens, 
and the resulting epithelial organoids were grown in 
matrix-embedded culture, as described previously [19, 
56]. After 9 days of culture, the acini were harvested, 
dissociated [20] and stained with specific cell markers. 
For MUC1/CD10 cell sorting experiments, single 
primary MECs from 3D cultures were stained with 
anti-MUC1 conjugated with fluorescein isothiocyanate 
(FITC; BD Biosciences) and anti-CD10 conjugated with 
phycoerythrin (PE; BD Biosciences). Single primary 
MECs were also sorted into subfractions on the basis of 
EpCAM, CD49f, CD10, MUC1, Thy1 and CD133, as 
described in [20]. For all flow cytometry experiments, 
forward scatter and side scatter plots were used to 
account for debris and aggregated cells. Single stained 
samples were used as compensation controls, and control 
samples consisted of unstained cells and/or IgG antibodies 
directly conjugated with FITC and PE (BD Biosciences). 
Cells were sorted on a FACSAria III cell sorter (BD 
Biosciences) in the Flow Cytometry Centre at the 
Westmead Millennium Institute. Analysis was performed 
using FACS Diva software (v6.1.2, BD Biosciences).
RNA preparation and qPCR
Sorted primary MECs were maintained at 4°C 
and collected by centrifugation. RNA was harvested 
with the Absolutely RNA Microprep Kit (Stratagene) 
according to the manufacturer’s instructions, and reverse 
transcribed with the High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). The cDNA was 
amplified by Platinum SYBR Green qPCR Supermix (Life 
Technologies, Inc.) on a Rotor-gene 6000 real-time cycler 
(Corbett Research, Australia). The TATA-binding protein 
(TBP) was used as an internal control gene, and primers 
used were as described in [20].
Immunohistochemistry
Matrigel cultures or thrombin clots were fixed, 
paraffin-embedded, cut into 2-µm sections, and antigens 
retrieved [57]. Where indicated, sequential sections were 
cut as mirror sections, to permit staining of opposite, 
or mirror faces, of the same cells in each section. 
Immunoperoxidase (IPX) staining was performed as 
previously published [58]. For dual immunofluorescence 
(IF) staining on all sample types, antigens were revealed 
sequentially by incubation of ERα (Novocastra) and PR 
(AB; Novocastra) primary antibodies. This was followed 
by detection by a biotinylated goat anti-mouse secondary 
antibody (Dakocytomation, Glostrup, Denmark) and a 
streptavidin-conjugated fluorescent label (Alexa 594 or 
488; Life Technologies, Inc.). It was critical to apply the 
ER antibody first, rather than PR, in order to detect each 
HR accurately, as using the reverse sequence results in 
underestimation of ER protein expression, and all steroid 
receptor-positive cells appear predominantly red/orange in 
colour with a distinct absence of green nuclei, which are 
clearly present when the PR antibody is applied second 
(Supp Fig 6). Selected sections were also stained with 
Ki67 (Dakocytomation, Glostrup, Denmark) primary 
antibody followed by detection by a biotinylated goat 
anti-rabbit. All sections were mounted in Prolong Gold 
antifade reagent containing the nuclear counter-stain DAPI 
(Life Technologies, Inc.). To ensure antibody specificity, 
adjacent sections were stained without the primary 
antibody, using the biotinylated secondary antibody and 
streptavidin-conjugated fluorescent label only. 
For mouse tissue sections, formalin fixed paraffin 
embedded sections were dewaxed, dehydrated and 
antigen retrieval performed with pH6 retrieval solution 
(Dako S1699) in a pressure cooker at 125°C for 30 sec. 
Endogenous peroxidase was blocked by 3% H2O2 and 
sections were stained with an antibody to ERα (Santa 
Cruz MC20 SC-542) or PRA and PRB (Dako A0098) 
for 30 mins at RT. The sections were then incubated with 
Envision rabbit HRP secondary (Dako K4002) for 30 
min at RT prior to application of 3,3’Diaminobenzidine 
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plus tertiary substrate (Dako K3468) for 10 mins at RT. 
Sections were counter stained with hematoxylin and slides 
were imaged with a NanoZoomer (Hamamatsu Photonics, 
Japan) slide scanner at 400x magnification. 
Quantitation of IF staining
Automated quantitation of normal, pre-invasive 
and breast tumor samples which had been dual stained 
for ER and PR was performed using the “cell scoring” 
module of MetaMorph® software program (version 7.7.5; 
Molecular Devices). The number of cells counted varied 
depending on the size of the section or TMA core, with an 
average of approximately 3000 cells counted per sample. 
Quantitation of luminal CK18+, myoepithelial p63+ and 
Ki67+ cells was performed beforehand, as published in 
[34]. 
Statistical methods
Two-sample comparison between subgroups used 
the Mann-Whitney U test to establish the distribution of 
the steroid receptor expression in normal, premalignant 
lesion and tumor groups, and Spearman’s rank correlation 
coefficient used to examine the association of between 
lineage composition and steroid receptor expression on 
SPSS software (Version 19, SPSS Inc., Chicago IL).
TLDA analysis method
The expression correlations of ER and PR transcripts 
in a cohort of 116 breast tissue samples were profiled on 
Taqman Low-Density Arrays (TLDA), as carried out in 
[35]. Briefly, we employed custom designed micro-fluidic 
TLDAs from ABI, which included probes for 48 nuclear 
receptors, 238 co-regulators and 16 internal control genes. 
The 116 breast tissue samples included four groups: ER+ 
(n=33), ER- (n =33), premenopausal normal (n =30), and 
postmenopausal normal (n = 20). TLDAs were analysed 
by relative quantification (ΔCt). The geNorm algorithm 
implemented in the Integromics StatMiner software 
package was used to select the most stable house-keeping 
genes as reference for normalisation. The Ct values of 
each assayed gene were then normalised against the 
median of the selected house-keeping genes to obtain the 
ΔCt values. The pairwise Spearman Rank Correlation 
Coefficient of ΔCt values was calculated between ER and 
PR, and between each of the two genes against all other 
nuclear receptors and co-regulators, which were profiled 
on the array. Ingenuity Pathway Analysis (Ingenuity® 
Systems,. www.ingenuity.com). was used to analyse 
pathway enrichment in particular subgroups of this cohort. 
To determine whether there were binding sites for ER or 
PR in the proximity of genes of interest, we interrogated 
the ChIP-Seq datasets described in Clarke and Graham 
(2012) (GEO accession GSE31130) [39] and Schmidt et 
al (2010) (ArrayExpress accession E-TABM-828) [59]. 
ChIP-Seq data were aligned to human genome build hg19 
and binding peaks were identified using MACS1.4 [60] 
with default parameters. A binding site was considered to 
be near to the gene of interest if it was within 50 kb of the 
transcription start site. 
Prognostic values of genes highly correlated with 
both ER and PR in breast cancers
The association between patient survival and 
expression level of genes highly correlated with both ER 
and PR in breast cancers were examined in a large publicly 
available breast cancer microarray dataset of 1853 samples 
[40]. The normalised expression value as published by 
the METABRIC study was used to calculate the pairwise 
Spearman Rank Correlation Coefficient between ER or PR 
against all other genes profiled on the Illumina HT-12v3 
array. Pairwise correlation coefficients were calculated 
separately for the discovery (EGAD00010000210) 
and validation (EGAD00010000211) cohort of the 
METABRIC study. This cohort included 721 Luminal 
A tumors (of which 669 had clinical follow-up data) 
and 492 Luminal B tumors (of which 454 had clinical 
follow-up data) [40]. Genes that correlate with both ER 
and PR (Spearman Rank Correlation >= 0.5) in both 
the METABRIC discovery and validation cohorts were 
retained to be included in the ER-PR gene signature 
(18 genes). Each patient microarray sample was then 
assigned a risk score calculated as a weighted average 
of the expression levels of the 18 ER-PR signature genes 
using the “sig.score” function from the Genefu R package. 
Samples were then stratified into 2 risk groups based on 
the assigned risk scores. The low-risk group comprises 
samples with risk scores in the bottom tertile, and the high-
risk group comprises of samples with risk scores in the top 
2 tertiles. Kaplan Meier analysis was performed to test 
the difference in probability of patient survival of the two 
risk groups. The association between risk scores calculated 
based on expression of the 18 ER-PR signature genes 
with patient survival was also tested by Cox Regression 
adjusted for Nodal status and ER and PR expression. 
The significant association between patient survival and 
expression of genes correlated with both ER and PR in 
breast cancers was validated in additional independent 
breast cancer microarray datasets (GSE25055, GSE25065 
and GSE7390) profiled on the Affymetrix Human Hg133A 
arrays. For these Affymetrix microarray datasets, fRMA 
normalized expression values were downloaded from 
InSilicoDb. The fRMA normalization algorithm utilizes 
pre-computed estimates of probe-specific effects and 
variances obtained from large publicly available databases. 
These pre-computed values are then used in concert with 
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information from new array(s) for normalization and 
summarization allowing datasets processed separately to 
be compared. A risk score was assigned to each microarray 
sample and the association between the calculated risk 
scores and patient survival determined as described above.
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